Our coverage team assesses the current state of the opioid litigation, including MDL basics and recent decisions including the Oklahoma public nuisance ruling against Johnson & Johnson. We also discuss how the litigation could affect specific companies, discussing Purdue Pharma’s tactics to stay litigation and, beyond Purdue, how potential opioid litigation-related liabilities could rank in relation to outstanding debt at Endo International and Teva Pharmaceuticals.